It appears you're using an older browser. BioHiTech.com will work better for you if you upgrade your browser or switch to another browser.
BioHiTech Global Reports First Quarter 2017 Results
-- Q1 2017 revenue increased 28% through growth in recurring rental and services revenue and equipment sales
-- Q1 2017 gross profit increases 75% due to improving economies of scale

CHESTNUT RIDGE, N.Y., May 16, 2017 /PRNewswire/ -- BioHiTech Global, Inc. ("BioHiTech" or the "Company") (OTCQB: BHTG), a green technology company that develops and deploys innovative and disruptive waste management technologies, reported financial results for the first quarter of 2017 ended March 31, 2017. 

Business Highlights

  • Began the Commercial Launch of its new Revolution Series Digesters - The Company debuted the Revolution Series Seed and Sprout Digesters and began select pilot programs in March 2017. The new units offer a cost-effective disposal solution targeting a market of more than 1.5 million lower volume food waste generators including full and quick service restaurants, coffee shops, hospitality companies and other specialty food service providers. They have a compact design, operate on standard 115 Volt power and are easily connected to standard plumbing.
  • Acquired 17.2% equity interest in the nation's first MBT municipal solid waste recovery facility to utilize HEBioT technology - The state-of-the-art waste-to-solid fuel plant, scheduled to begin commissioning in Q4 2017, utilizes a patented mechanical biological treatment ("MBT") process to convert municipal solid waste into an EPA approved solid recovered fuel that is currently deployed in nine locations throughout Europe. BioHiTech controls the exclusive development rights to this technology developed by Entsorgafin S.p.A., an Italian engineering firm, in eleven Northeast states and the District of Columbia. The plant, located in Martinsburg, West Virginia, is expected to reduce landfill usage by as much as 80%.
  • Secured site in New York State for its second MBT municipal solid waste recovery facility - The Company entered into a contract with the Town of New Windsor, New York to acquire a 12-acre site planned for the Company's second MBT facility. The agreement includes a negotiated host community fee for the Town of New Windsor.
  • Appointed former Walmart executive Anthony Fuller to its Board of Directors - Mr. Fuller recently completed a thirty-year career at Walmart culminating with his role as Senior Vice President. During his tenure, he served as one of twelve executives on Walmart's Global Sustainability Steering Committee providing direction for all of the company's sustainability efforts. He also served as the chairman of Walmart's real estate transaction committee and real estate finance committee.
  • Launched BioHiTech Cirrus™ 2.2 mobile app providing real-time supply chain data analytics - Cirrus™ 2.2 delivers improved information accessibility and transparency into food waste creation, providing valuable data analytics to identify supply chain inefficiencies in real-time in order to reduce waste and improve operating margins.

Frank E. Celli, CEO commented, "During the first quarter, we achieved significant growth in revenue from our Digester business while we made great progress in positioning our company to fully commercialize our environmentally-friendly and cost-effective waste management technologies. The launch of the Revolution Series Digesters opens a vast untapped market for our Company and we are very excited by the initial response from potential customers.  Our investment in the West Virginia MBT plant and our plans for a second plant in New York establishes the foundation for a very profitable long-term revenue stream with substantial room for growth.  As we further these efforts and work to generate additional revenue opportunities, we are confident that we can build increasing value for the benefit of our stockholders."

Q1 Financial Highlights

Revenue: Revenue in Q1 2017 was $591,000, a 27.7% increase compared to revenue of $463,000 in Q1 2016. Recurring rental, services and maintenance revenue grew by 17.2% and represented 60.7% of total revenue.  Revenue from equipment sales rose by 48.0% to reach $232,000.  This significant improvement in equipment sales was primarily attributable to an increase in international reseller activity in areas where equipment leasing is not as well established as the retail sales model.

Gross Profit: Q1 2017 gross profit was $199,000, a 74.5% increase compared to gross profit of $114,000 in Q1 2016. Gross profit margin increased by 9.0 percentage points to reach 33.7%. Rental, service and maintenance gross margin increased by 7.5 percentage points to 27.8%, primarily due to improved economies of scale. Equipment sales gross margin grew by 9.7 percentage points to 42.9% due to an increase in higher margin international sales.

Operating Expenses: Q1 2017 operating expenses increased by 22.7% to $1.9 million compared to $1.6 million in Q1 2016.  The increase in operating expenses was mainly due to a $380,000 increase in equity-based compensation for professional fees related to marketing and investor relations.  Total expenses for SG&A and R&D remained fairly consistent year over year. 

Operating Loss: Q1 2017 operating loss was $(1.7 million) compared to $(1.5 million) in Q1 2016. The increase in operating loss was a result of the increase in operating expenses partially offset by the increase in gross profit.  While the Company's operating loss increased, cash used in operating activities declined by $641,000 to total $936,000 as compared to $1,577,000 million in Q1 of the prior year.

Net Loss: The Company recorded a Q1 2017 net loss attributable to shareholders was $(2.0 million) or $(0.25) on 8.2 million shares versus a net loss of ($1.6 million) or $(0.20) on 8.2 million shares in Q1 2016. 

Brian C. Essman, CFO commented, "The first quarter delivered broad based growth and improved operational results for our Company. Recurring revenue related to our Digester rental business increased by 17% while equipment sales grew by 48%.  The increase in revenue led to a 75% increase in gross profit and helped us reduce cash used in operating activities by 41%.  We continue to prudently invest in our technology for providing sophisticated data analytics for our customers while we move forward with the commercialization efforts for our MBT business.  We expect future progress over the course of 2017 as we continue to execute on our long term growth plans to create significant value for the benefit of our stockholders."

Additional information can be found in the Company's Form 10-Q filed with the United States Securities and Exchange Commission (SEC) on May 15, 2017. 

About BioHiTech Global
BioHiTech Global (OTCQB: BHTG), "The Company" headquartered in Chestnut Ridge NY, develops and deploys innovative and disruptive waste management technologies. The combined offerings of BioHiTech Global offer our customers a full suite of technology based disposal options capable of having a significant impact on waste generation while providing a true zero landfill environment. With options for both on and off site biological treatment of waste, BioHiTech Global is a leader in zero waste solutions for businesses and municipalities.  For more information, please visit www.biohitechglobal.com.

Forward Looking Statements
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of BioHiTech Global, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. BioHiTech Global, Inc. assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission ("SEC"). There may be other factors not mentioned above or included in the BioHiTech's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. BioHiTech Global, Inc. assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

Company Contact:
BioHiTech Global, Inc.
Lisa Giovannielli
Director, Corporate Communications
Direct: 845-262-1081
[email protected]
www.biohitechglobal.com

 

BioHiTech Global, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)




Three Months Ended March 31,




2017



2016


Revenue









Rental, service and maintenance


$

358,537



$

305,862


Equipment sales



232,143




156,865


Total revenue



590,680




462,727


Cost of revenue









Rental, service and maintenance



258,939




243,801


Equipment sales



132,491




104,765


Total Cost of revenue



391,430




348,566


Gross profit



199,250




114,161


Operating expenses









Selling, general and administrative



1,064,629




1,028,649


Research and development



187,501




183,931


Professional fees



649,623




335,845


Depreciation and amortization



29,774




25,774


Total operating expenses



1,931,527




1,574,199


Loss from operations



(1,732,277)




(1,460,038)


Other (expense) income









Interest income



-




355


Interest expense



(296,256)




(149,159)


Total other expense



(296,256)




(148,804)


Net loss



(2,028,533)




(1,608,842)


Other comprehensive income (loss)









Foreign currency translation adjustment



(7,164)




7,906


Comprehensive loss


$

(2,035,697)



$

(1,600,936)











Net loss per share - basic and diluted


$

(0.25)



$

(0.20)


Weighted average number of common shares outstanding - basic and diluted



8,229,712




8,229,712


 

 

BioHiTech Global, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets (Unaudited) 




March 31,



December 31,




2017



2016


Assets









Current Assets









Cash


$

320,776



$

325,987


Accounts and note receivable, net



125,489




140,130


Inventory



439,869




706,017


Prepaid expenses and other current assets



63,724




21,865


Total Current Assets



949,858




1,193,999


Equipment on operating leases, net



1,150,227




1,023,404


Equipment, fixtures and vehicles, net



50,680




54,356


Intangible assets, net



242,542




267,042


Investment in Entsorga West Virginia, LLC



1,034,028




-


MBT facility development costs



36,512




-


Other assets



13,500




13,500


Total Assets


$

3,477,347



$

2,552,301


Liabilities and Stockholders' Deficit









Current Liabilities:









Line of credit


$

2,463,736



$

2,463,736


Accounts payable



1,262,708




1,197,277


Accrued interest payable



862,150




411,917


Accrued expenses



596,391




522,727


Warrant liability



105,188




-


Deferred revenue



84,038




61,879


Notes payable



100,000




100,000


Notes payable - related party



275,000




275,000


Unsecured subordinated convertible notes, including related parties of $2,550,000, net of deferred financing costs of $68,846



3,756,154




-


Convertible note, net of deferred financing cost of $8,000 and original issue discounts of $30,058



71,942




-


Advance from related party



463,027




1,213,027


Customer deposits



107,165




36,131


Long-term debt, current portion



7,993




8,525


Total Current Liabilities



10,155,492




6,290,219


Promissory note - related party



4,500,000




2,500,000


Long term accrued interest



48,485




253,000


Unsecured subordinated convertible notes, including related parties of 1,750,000, and $3,800,000, net of deferred financing costs of $25,536 and $118,866 as of March 31, 2017 and December 31, 2016, respectively



1,874,464




4,956,134


Long-term debt, net of current portion



9,473




11,048


Total Liabilities



16,587,914




14,010,401


Commitments and Contingencies









Stockholders' Deficit









Preferred stock, $0.0001 par value; 10,000,000 shares authorized; none issued



-




-


Common stock, $0.0001 par value, 20,000,000 shares authorized; 8,229,712 shares issued and outstanding as of March 31, 2017 and December 31, 2016



823




823


Additional paid in capital



9,987,554




9,604,324


Accumulated deficit



(23,100,699)




(21,072,166)


Accumulated other comprehensive gain



1,755




8,919


Total Stockholders' Deficit



(13,110,567)




(11,458,100)


Total Liabilities and Stockholders' Deficit


$

3,477,347



$

2,552,301


 

 

BioHiTech Global, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows (Unaudited)




Three Months Ended March 31,




2017



2016


Cash flows from operating activities:









Net loss:


$

(2,028,533)



$

(1,608,842)


Adjustments to reconcile net loss to net cash used in operations:









Depreciation and amortization



104,354




92,286


Provision (recovery) - bad debts



22,962




(10,384)


Stock based employee compensation



88,025




138,390


Fees paid in stock



275,148




-


Fees to be paid in warrants



105,187




-


Interest resulting from amortization of financing costs



24,484




-


Changes in operating assets and liabilities



471,960




(187,969)


Net cash used in operations



(936,413)




(1,576,519)











Cash flow from investing activities:









Sale of used machinery and equipment



13,149




-


Investment in Entsorga West Virginia, LLC



(1,034,028)




-


Increase in MBT facility development costs



(36,512)




-


Purchases of equipment, fixtures and vehicles



(1,597)




(1,842)


Net cash (used in) provided by investing activities



(1,058,988)




(1,842)











Cash flows from financing activities:









Net change in line of credit



-




(25,017)


Proceeds from convertible notes with warrants and beneficial conversion feature



100,000




-


Proceeds from series convertible notes



150,000




250,000


Deferred financing costs incurred



(8,000)




(82,730)


Repayments of long-term debt



(2,107)




(2,042)


Related party:









Net increases (decreases) of advances



463,027




(710,000)


Proceeds from promissory notes



786,973




190,000


Repayments of promissory notes



-




(200,000)


Proceeds from convertible notes



500,000




2,250,000


Net cash provided by financing activities



1,989,893




1,670,211


Effect of exchange rate on cash



297




7,906


Net change in cash



(5,211)




99,756


Cash - beginning of period



325,987




39,195


Cash - end of period


$

320,776



$

138,951


 

SOURCE BioHiTech Global, Inc.


print email rss
Price Data
OTCQBBHTG
OTCQBBHTG

Contact BioHiTech Global Investor Relations

Investor Relations Contact:      Legal Contact:       Transfer Agent:
BioHiTech Global     Kane Kessler, P.C.      VStock Transfer, LLC 
Lisa Giovannielli     Peter Campitiello, Esq.      Direct: 212-828-8436
Direct: 845-262-1081     Direct: 212-519-5109      [email protected]
[email protected]     [email protected]     www.vstocktransfer.com
www.biohitechglobal.com            
             
Media Contact:      Sales Contact:      BioHiTech Global
BioHiTech Global     BioHiTech Global      80 Red Schoolhouse Road
Lisa Giovannielli     Lisa Giovannielli      Suite 101
Direct:  845-262-1081     Direct: 845-262-1081      Chestnut Ridge, NY 10977
[email protected]      [email protected]      View Map
www.biohitechglobal.com      www.biohitech.com      

 

Copyright (c) 2017 BioHiTech Global